{"protocolSection":{"identificationModule":{"nctId":"NCT01208233","orgStudyIdInfo":{"id":"A9541004"},"secondaryIdInfos":[{"id":"2010-021414-32","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke","officialTitle":"A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of Pf-03049423 In Subjects With Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2016-01","overallStatus":"TERMINATED","whyStopped":"See termination reason in detailed description.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-12"},"primaryCompletionDateStruct":{"date":"2013-12","type":"ACTUAL"},"completionDateStruct":{"date":"2013-12","type":"ACTUAL"},"studyFirstSubmitDate":"2010-09-22","studyFirstSubmitQcDate":"2010-09-22","studyFirstPostDateStruct":{"date":"2010-09-23","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-02-19","resultsFirstSubmitQcDate":"2016-01-22","resultsFirstPostDateStruct":{"date":"2016-02-19","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-01-22","lastUpdatePostDateStruct":{"date":"2016-02-19","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy of PF-03049423, relative to placebo, in subjects with ischemic stroke following 90 days of therapy. The study will also explore the relationship between PF-03049423 concentration and blood pressure.","detailedDescription":"The interim analysis for the POC study A9541004 demonstrated futility, and the study was stopped on the 6th of November 2013. There were no signals of serious safety concern."},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["Phase 2 Ischemic stroke Safety and efficacy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":181,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1 mg PF-03049423","type":"EXPERIMENTAL","interventionNames":["Drug: PF-03049423"]},{"label":"3 mg of PF-03049423","type":"EXPERIMENTAL","interventionNames":["Drug: PF-03049423"]},{"label":"6 mg of PF-03049423","type":"EXPERIMENTAL","interventionNames":["Drug: PF-03049423"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"PF-03049423","description":"1 mg of PF-03049423 daily for 90 days","armGroupLabels":["1 mg PF-03049423"]},{"type":"DRUG","name":"PF-03049423","description":"3 mg of PF-03049423 daily for 90 days","armGroupLabels":["3 mg of PF-03049423"]},{"type":"DRUG","name":"PF-03049423","description":"6 mg of PF-03049423 daily for 90 days","armGroupLabels":["6 mg of PF-03049423"]},{"type":"OTHER","name":"Placebo","description":"Placebo of PF-03049423 daily for 90 days","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Any Abnormal Laboratory Test Results (Part 1* and 2)","description":"The total number of participants with laboratory test abnormalities (without regard to baseline abnormality) was assessed. \\*This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.","timeFrame":"Day 1 (Baseline) up to Day 90"},{"measure":"Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern (Part 1* and 2)","description":"Vital signs included blood pressure (BP; supine, sitting and standing) and pulse rate. Vital signs criteria of potential clinical concern were 1), BP: systolic BP (SBP) greater than or equal to (\\>=) 30 or 50 millimeters of mercury (mm Hg) change from grand baseline in same posture, systolic less than (\\<) 90 mm Hg; diastolic BP (DBP) \\>=20 mm Hg change from grand baseline in same posture, diastolic \\<50 mm Hg; 2), pulse rate (supine, sitting and standing): \\<40 or greater than (\\>) 120 beats per minute (bpm); Standing: \\<40 or \\>140 bpm. \\*This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.","timeFrame":"Day 1 (Baseline) up to follow-up (28 days after Day 90)"},{"measure":"Number of Participants With Electrocardiograms (ECGs) Data Met Criteria of Potential Clinical Concern (Part 1* and 2)","description":"ECG criteria of potential clinical concern were 1), PR interval: \\>=300 milliseconds (msec); \\>=25% increase when baseline \\>200 msec; or increase \\>=50% when baseline \\<=200 msec; 2), QRS interval: \\>=140 msec; \\>=50% increase from baseline; 3), QT interval: \\>=500 msec, QTc interval using Fridericia's formula (QTcF interval): absolute value \\>=450 - \\<480 msec, \\>=480-\\<500 msec, \\>=500 msec; absolute change 30 - \\<60, \\>=60 msec. \\*This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.","timeFrame":"Day 1 (Baseline) to Day 90"},{"measure":"Number of Participants With Significant Change in Physical Examination Findings (Part 1* and 2)","description":"The complete physical examination included examination of the skin, eyes, ears, throat, neck, cardiac, respiratory, gastrointestinal, and musculoskeletal systems. The limited physical examination included examination of the cardiac, respiratory, gastrointestinal, and musculoskeletal systems. \\*This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.","timeFrame":"Day 1 (Baseline) up to Day 90"},{"measure":"Number of Participants With Significant Change in Neurological Examination Findings (Part 1* and 2)","description":"The complete neurological examination included an assessment of the motor, sensory, cranial nerves, reflexes, mental status and associated motor functions. The limited neurological exam could examine the same categories of neurologic assessments as the full examination, but would differ by the depth in the examination. The examination was required to be done to the extent needed to assess the participant for any potential changes in neurological status, as determined by the Investigator, but had to always include an assessment of motor, vision and hearing. \\*This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.","timeFrame":"Day 1 (Baseline) up to Day 90"},{"measure":"Number of Participants With Suicidal Behavior and/or Ideation as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) (Part 1* and 2)","description":"Data were mapped to Columbia-Classification Algorithm of Suicide Assessment (C-CASA) event codes. C-SSRS assessed if participant experienced: completed suicide (Code 1), suicide attempt (Code 2) (Response of \"Yes\" on \"actual attempt\"), preparatory acts toward imminent suicidal behavior (Code 3) (\"Yes\" on \"aborted attempt\", \"interrupted attempt\", \"preparatory acts or behavior\"), suicidal ideation (Code 4) (\"Yes\" on \"wish to be dead\", \"non-specific active suicidal thoughts\", \"active suicidal ideation with methods without intent to act/some intent to act without specific plan or with specific plan and intent), self-injurious behavior, no suicidal intent (Code 7) (\"Yes\" on \"Has participant engaged in non-suicidal self-injurious behavior\"). Number of participants with \"Yes\" response for any of above mentioned categories was assessed. \\*This was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for it were not reported separately, Part 1 and 2 data were reported together.","timeFrame":"Day 7 (Baseline) up to follow up (28 days after Day 90)"},{"measure":"Percentage of Participants With Modified Rankin Scale (mRS) Less Than or Equal to (<=2) at Day 90 (Part 2)","description":"The mRS is a 6-point scale of functional recovery. The scale grades participants as having no symptoms (0), minor symptoms (1), minor handicap (2), moderate handicap (3), moderately severe handicap (4), severe handicap (5), or death (6).","timeFrame":"Day 90"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Box and Blocks (B&B) Test at Day 90 for Paretic Hand (Part 2)","description":"The B\\&B test is a measure of manual dexterity. The B\\&B apparatus consists of a box divided into 2 sections and 1-inch hardwood blocks. The blocks began in the compartment of the test box to the dominant side of the participant. The participant was required to transfer the blocks one at a time to the other side of the box as quickly as possible in 1 minute using the non-paretic hand. The box was then turned so all the blocks were in the same side as the paretic hand. The participant was then required to do the test with his/her paretic hand. The participant was told that if more than 1 block was picked up at a time it was to only count as 1 block. The participant was also told that their fingertips needed to cross the partition for the block to be counted. The performance measure for this task was the number of blocks moved within 1 minute.","timeFrame":"Day 1 (Baseline), Day 90"},{"measure":"Change From Baseline in Box and Blocks (B&B) Test at Day 90 for Paretic to Non-paretic Hand Ratio (Part 2)","description":"The B\\&B test is a measure of manual dexterity. The B\\&B apparatus consists of a box divided into 2 sections and 1-inch hardwood blocks. The blocks began in the compartment of the test box to the dominant side of the participant. The participant was required to transfer the blocks one at a time to the other side of the box as quickly as possible in 1 minute using the non-paretic hand. The box was then turned so all the blocks were in the same side as the paretic hand. The participant was then required to do the test with his/her paretic hand. The participant was told that if more than 1 block was picked up at a time it was to only count as 1 block. The participant was also told that their fingertips needed to cross the partition for the block to be counted. The performance measure for this task was the number of blocks moved within 1 minute.","timeFrame":"Day 1 (Baseline), Day 90"},{"measure":"Change From Baseline in Hand Grip Strength Test at Day 90 for Paretic and Non-paretic Hands (Part 2)","description":"The Hand Grip Strength Test measures the maximum isometric strength of the hand and forearm muscles. The participant was required to squeeze the dynamometer with maximum isometric effort while sitting with shoulder adducted and neutrally roated, elbow flexed at 90 degrees and the forearm in neutral position and wrist between 0 to 30 degrees dorsiflexion and a 0 to 15 degrees ulnar deviation. The participant performed this task 3 times with each hand, starting with the non-paretic hand. The performance measure for this task was the average score measured in pounds of pressure exerted.","timeFrame":"Day 1 (Baseline), Day 90"},{"measure":"Change From Baseline in Hand Grip Strength Test at Day 90 for Paretic to Non-paretic Hand Ratio (Part 2)","description":"The Hand Grip Strength Test measures the maximum isometric strength of the hand and forearm muscles. The participant was required to squeeze the dynamometer with maximum isometric effort while sitting with shoulder adducted and neutrally roated, elbow flexed at 90 degrees and the forearm in neutral position and wrist between 0 to 30 degrees dorsiflexion and a 0 to 15 degrees ulnar deviation. The participant performed this task 3 times with each hand, starting with the non-paretic hand. The performance measure for this task was the average score measured in pounds of pressure exerted.","timeFrame":"Day 1 (Baseline), Day 90"},{"measure":"Percentage of Participants With mRS (0-1) at Day 90 (Part 2)","description":"The mRS is a 6-point scale of functional recovery. The scale grades participants as having no symptoms (0), minor symptoms (1), minor handicap (2), moderate handicap (3), moderately severe handicap (4), severe handicap (5), or death (6).","timeFrame":"Day 90"},{"measure":"Percentage of Participants With National Institutes of Health Stroke Scale (NIHSS) (0-1) at Day 90 (Part 2)","description":"The NIHSS is a graded 11-item neurological examination rating speech and language, cognition, visual field deficits, motor and sensory impairments and ataxia used for the clinical assessment of acute stroke therapy. The maximum total score is 42 in a participant with a severe neurological deficit; the minimum score is 0 in a participant without gross neurological deficits.","timeFrame":"Day 90"},{"measure":"Change From Baseline in NIHSS at Day 90 (Part 2)","description":"The NIHSS is a graded 11-item neurological examination rating speech and language, cognition, visual field deficits, motor and sensory impairments and ataxia used for the clinical assessment of acute stroke therapy. The maximum total score is 42 in a participant with a severe neurological deficit; the minimum score is 0 in a participant without gross neurological deficits.","timeFrame":"Day 1 (Baseline), Day 90"},{"measure":"Percentage of Participants With Barthel Index (BI) >= 95 and BI =100 at Day 90 (Part 2)","description":"The BI is an index of independence to score the ability of a participant with a neuromuscular or musculoskeletal disorder to care for him or herself. The index rates a participant's ability on the following 10 activities: feeding, moving from wheelchair to bed, personal toilet, getting on and off toilet, bathing self, walking on level surface, ascending and descending stairs, dressing, controlling bowels and controlling bladder. The maximum total score is 100 in a participant without functional impairment; the minimum score is 0 in a participant with major functional impairment.","timeFrame":"Day 90"},{"measure":"BI at Day 90 (Part 2)","description":"The BI is an index of independence to score the ability of a participant with a neuromuscular or musculoskeletal disorder to care for him or herself. The index rates a participant's ability on the following 10 activities: feeding, moving from wheelchair to bed, personal toilet, getting on and off toilet, bathing self, walking on level surface, ascending and descending stairs, dressing, controlling bowels and controlling bladder. The maximum total score is 100 in a participant without functional impairment; the minimum score is 0 in a participant with major functional impairment.","timeFrame":"Day 90"},{"measure":"Domains of Interest: Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Coding Sub Test at Day 90 (Part 2)","description":"The test uses a reference key, the participant had 90 seconds to pair specific numbers with given geometric figures. Responses could be written or oral. The performance measure for this task was the total number of correct responses.","timeFrame":"Day 1 (Baseline), Day 90"},{"measure":"Domains of Interest: Change From Baseline in RBANS Naming Sub Test at Day 90 (Part 2)","description":"This test requires the participant to name 10 objects drawn in ink. The tester asked the participant to identify the picture. The participant had 20 seconds to respond to each picture presented. The performance measure was the number of objects named correctly.","timeFrame":"Day 1 (Baseline), Day 90"},{"measure":"Domains of Interest: Change From Baseline in Line Cancellation Test [(L+R)/28 × 100%, (L/14) × 100%, (R/14) × 100%)] at Day 90 (Part 2)","description":"The participant was presented with a page that had lines placed across the page. The participant was required to cross out all the lines on the page using their non-paretic hand after the tester had demonstrated what was required by crossing out the center line. The performance measure for this task was the total number of omissions made expressed as a percentage of the total number of items in the test. The test contains 4 variables: (L+R)/28 × 100%, (L/14) × 100%, (R/14) × 100%, and (L-R)/(L+R), where L = number of lines crossed on the left side of the paper; R = number of lines crossed on the right side of the paper.","timeFrame":"Day 1 (Baseline), Day 90"},{"measure":"Domains of Interest: Change From Baseline in Line Cancellation Test at Day 90 [(L-R)/(L+R)] (Part 2)","description":"The participant was presented with a page that had lines placed across the page. The participant was required to cross out all the lines on the page using their non-paretic hand after the tester had demonstrated what was required by crossing out the center line. The performance measure for this task was the total number of omissions made expressed as a percentage of the total number of items in the test. The test contains 4 variables: (L+R)/28 × 100%, (L/14) × 100%, (R/14) × 100%, and (L-R)/(L+R), where L = number of lines crossed on the left side of the paper; R = number of lines crossed on the right side of the paper.","timeFrame":"Day 1 (Baseline), Day 90"},{"measure":"Domains of Interest: Change From Baseline in Recognition Memory Test at Day 90 (Part 2)","description":"This test assesses the ability to recognize pictures of objects. The participant was presented a series of pictures, a subset of which were the objects presented in the RBANS Naming Sub Test. After each picture was presented, the participant indicated either manually (ie, affirmative head nod) or verbally whether the picture was seen previously. The participant was given 5 seconds per picture to respond. The performance measure for this task was the total number of pictures correctly identified.","timeFrame":"Day 1 (Baseline), Day 90"},{"measure":"Gait Velocity Test at Day 90 (Part 2)","description":"The 10-meter walk test requires a 20 meter straight path, with 5 meters for acceleration, 10 meters for steady state walking, and 5 meters for deceleration. Markers were placed at the 5 and 15 meter positions along the path. The participant began to walk \"at a comfortable pace\" at 1 end of the path, and continued walking until he/she reached the other end. The rater used a stopwatch to determine how much time it took for the participant to traverse the 10 meter center of the path, starting the stopwatch as soon as the participant's limb crossed the first marker and stopping the stopwatch as soon as the participant's limb crossed the second marker.","timeFrame":"Day 90"},{"measure":"Plasma Concentrations of PF-03049423 (Part 1 and 2)","timeFrame":"Days 1, 2, 7, 14, 30, 60 and 90"},{"measure":"Change From Baseline in Box and Blocks (B&B) Test at Day 90 for Non-paretic Hand (Part 2)","description":"The B\\&B test is a measure of manual dexterity. The B\\&B apparatus consists of a box divided into 2 sections and 1-inch hardwood blocks. The blocks began in the compartment of the test box to the dominant side of the participant. The participant was required to transfer the blocks one at a time to the other side of the box as quickly as possible in 1 minute using the non-paretic hand. The box was then turned so all the blocks were in the same side as the paretic hand. The participant was then required to do the test with his/her paretic hand. The participant was told that if more than 1 block was picked up at a time it was to only count as 1 block. The participant was also told that their fingertips needed to cross the partition for the block to be counted. The performance measure for this task was the number of blocks moved within 1 minute.","timeFrame":"Day 1 (Baseline), Day 90"}],"otherOutcomes":[{"measure":"All-cause Mortality (Part 2)","description":"Deaths regardless causality were reported.","timeFrame":"The time began from the participant provided informed consent through 28 calendar days post last administration of investigational product."},{"measure":"Mortality Directly Related to Stroke (Part 2)","description":"Deaths caused by stroke were reported.","timeFrame":"The time began from the participant provided informed consent through 28 calendar days post last administration of investigational product."},{"measure":"Number of Participants With Neuro-worsening (Part 2)","description":"NIHSS change of 4 points or greater.","timeFrame":"Day 1 (Baseline) up to Day 90"},{"measure":"Number of Participants With SBP <100 mm Hg or SBP Decline >=30 mm Hg From Immediate Pre-dose Measurement, With or Without Neuro-worsening (Defined as an NIHSS Increase of 4 Points or Greater) Within 2 Hours Post-dose (Part 2)","timeFrame":"Day 1 (Baseline) up to Day 14"},{"measure":"Treatment-emergent Adverse Events (AEs) Resulting in Discontinuation of Study Drug (Part 2)","description":"An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.","timeFrame":"Day 1 (Baseline) up to follow-up (28 days after Day 90)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of ischemic stroke with an onset within 72 hours prior to start of study agent administration, male or female.\n* Supratentorial ischemic stroke involving the cortex documented by neurological exam and confirmed by MRI.\n* Stroke involving upper extremity.\n* Subjects who received thrombolytic therapy may be enrolled and the use of antiplatelet is acceptable.\n\nExclusion Criteria:\n\n* Any other severe acute or chronic medical or psychiatric condition besides the stroke.\n* Women of child bearing potential.\n* Uncontrolled hypertension.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Spain Rehabilitation Center","city":"Birmingham","state":"Alabama","zip":"35233","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"The Kirklin Clinic","city":"Birmingham","state":"Alabama","zip":"35233","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"University Hospital","city":"Birmingham","state":"Alabama","zip":"35294-3280","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Broward Health North","city":"Deerfield Beach","state":"Florida","zip":"33064","country":"United States","geoPoint":{"lat":26.31841,"lon":-80.09977}},{"facility":"Neurologic Consultant, P.A.","city":"Fort Lauderdale","state":"Florida","zip":"33308","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"Fawcett Memorial Hospital","city":"Port Charlotte","state":"Florida","zip":"33952","country":"United States","geoPoint":{"lat":26.97617,"lon":-82.09064}},{"facility":"Neurostudies, Inc.","city":"Port Charlotte","state":"Florida","zip":"33952","country":"United States","geoPoint":{"lat":26.97617,"lon":-82.09064}},{"facility":"Jagdish Sidhpura M.D.","city":"Columbus","state":"Georgia","zip":"31901","country":"United States","geoPoint":{"lat":32.46098,"lon":-84.98771}},{"facility":"Jose Canedo, M.D., West Georgia Neurology","city":"Columbus","state":"Georgia","zip":"31904","country":"United States","geoPoint":{"lat":32.46098,"lon":-84.98771}},{"facility":"St. Francis Hospital","city":"Columbus","state":"Georgia","zip":"31904","country":"United States","geoPoint":{"lat":32.46098,"lon":-84.98771}},{"facility":"Muscogee Manor & Rehabilitation Center","city":"Columbus","state":"Georgia","zip":"31907","country":"United States","geoPoint":{"lat":32.46098,"lon":-84.98771}},{"facility":"Medical Research & Health Education Foundation, Inc.","city":"Columbus","state":"Georgia","zip":"31909","country":"United States","geoPoint":{"lat":32.46098,"lon":-84.98771}},{"facility":"Parkview Hospital Randallia","city":"Fort Wayne","state":"Indiana","zip":"46805","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"Fort Wayne Neurological Center","city":"Fort Wayne","state":"Indiana","zip":"46845","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"Parkview Regional Medical Center","city":"Fort Wayne","state":"Indiana","zip":"46845","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"Parkview Research Center","city":"Fort Wayne","state":"Indiana","zip":"46845","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"Norwood Nursing Center","city":"Huntington","state":"Indiana","zip":"46750","country":"United States","geoPoint":{"lat":40.8831,"lon":-85.49748}},{"facility":"Massachusetts General Hospital/Department of Neurology","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Spaulding Rehabilitation Hospital","city":"Boston","state":"Massachusetts","zip":"02129","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Wayne State University","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Barnes-Jewish Hospital","city":"St. Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Rehabilitation Institute of St. Louis","city":"St. Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"UNC HealthCare","city":"Chapel Hill","state":"North Carolina","zip":"27514","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"UNC Department of Neurology Stroke Division","city":"Chapel Hill","state":"North Carolina","zip":"27599-7025","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"Investigational Drug Services at OU Medical Center","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Oklahoma University Health Sciences Center","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"OU Medical Center","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"OU Physicians Building","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Penn State Milton South Hershey Medical Center / Penn State College of Medicine","city":"Hershey","state":"Pennsylvania","zip":"17033","country":"United States","geoPoint":{"lat":40.28592,"lon":-76.65025}},{"facility":"Penn State Hershey Rehabilitation Hospital","city":"Hummelstown","state":"Pennsylvania","zip":"17036","country":"United States","geoPoint":{"lat":40.26537,"lon":-76.7083}},{"facility":"The Methodist Hospital Neurological Institute","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"The Methodist Hospital","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Voennomeditsinska Akademia - MBAL- Pleven, Otdelenie po Nervni bolesti","city":"Pleven","zip":"5800","country":"Bulgaria","geoPoint":{"lat":43.41667,"lon":24.61667}},{"facility":"MBAL Kaspela","city":"Plovdiv","zip":"4002","country":"Bulgaria","geoPoint":{"lat":42.15,"lon":24.75}},{"facility":"MBALNP \"Sveti Naum\" EAD, Klinika za Intenzivno Lechenie na Nervni Bolesti","city":"Sofia","zip":"1113","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Vtora Mnogoprofilna Bolnitsa za Aktivno Lechenie, Otdelenie po Nevrologia","city":"Sofia","zip":"1202","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"MBAL \"Tokuda Bolnitsa\", Otdelenie po nevrologiya","city":"Sofia","zip":"1407","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Universitetska mnogoprofilna bolnitsa za aktivno lechenie Aleksandrovska, Klinika po Nevrologia","city":"Sofia","zip":"1431","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"UMBAL Tsaritsa Yoanna, Klinika po nevrologia","city":"Sofia","zip":"1527","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Grey Nuns Community Hospital","city":"Edmonton","state":"Alberta","zip":"T6L 5X8","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Fakultni nemocnice u sv. Anny v Brne","city":"Brno","zip":"65691","country":"Czech Republic","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Fakultni nemocnice Plzen","city":"Plzen - Lochotin","zip":"304 60","country":"Czech Republic","geoPoint":{"lat":49.74747,"lon":13.37759}},{"facility":"CHU Pellegrin","city":"Bordeaux","zip":"33076","country":"France","geoPoint":{"lat":44.84044,"lon":-0.5805}},{"facility":"CHU La Pitie Salpetriere","city":"Paris Cedex 13","zip":"75651","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Klinikum Altenburger Land","city":"Altenburg","zip":"04600","country":"Germany","geoPoint":{"lat":50.98763,"lon":12.43684}},{"facility":"Universitaetsklinikum Essen, Neurologische Klinik","city":"Essen","zip":"45122","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Universitaetsklinikum Leipzig","city":"Leipzig","zip":"04103","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Klinikum Rechts der Isar, Neurologische Klinik","city":"Muenchen","zip":"81675","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}},{"facility":"Universitaetsklinikum Muenster","city":"Muenster","zip":"48149","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}},{"facility":"Universitaet Regensburg","city":"Regensburg","zip":"93053","country":"Germany","geoPoint":{"lat":49.01513,"lon":12.10161}},{"facility":"Dr. Kennessey Albert Korhaz-Rendelointezet, Neurologiai Osztaly","city":"Balassagyarmat","zip":"2660","country":"Hungary","geoPoint":{"lat":48.07296,"lon":19.29614}},{"facility":"Fovarosi Onkormanyzat Peterfy Sandor utcai Korhaz-Rendelointezet es Baleseti Kozpont/Neurologia","city":"Budapest","zip":"1076","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Semmelweis Egyetem AOK / Neurologiai Klinika","city":"Budapest","zip":"1083","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Honvedkorhaz-Allami Egeszsegugyi Kozpont, Ideggyogyaszati Osztaly","city":"Budapest","zip":"1134","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Orszagos Idegtudomanyi Intezet, Stroke-ambulancia","city":"Budapest","zip":"1145","country":"Hungary","geoPoint":{"lat":47.49801,"lon":19.03991}},{"facility":"Petz Aladar Megyei Oktato Korhaz, Neurologiai Osztaly","city":"Gyor","zip":"9024","country":"Hungary","geoPoint":{"lat":47.68333,"lon":17.63512}},{"facility":"KEM Hospital","city":"Pune","state":"Maharashtra","zip":"411011","country":"India","geoPoint":{"lat":18.51957,"lon":73.85535}},{"facility":"Max Super Speciality Hospital","city":"New Delhi","zip":"110017","country":"India","geoPoint":{"lat":28.63576,"lon":77.22445}},{"facility":"Seoul National University Bundang Hospital, Department of Neurology","city":"Seongnam-si","state":"Gyeonggi-do","zip":"463-707","country":"Korea, Republic of","geoPoint":{"lat":37.43861,"lon":127.13778}},{"facility":"Hallym University Sacred Heart Hospital, Department of Neurology","city":"Anyang-si","state":"Gyonggi-do","zip":"431-070","country":"Korea, Republic of","geoPoint":{"lat":37.3925,"lon":126.92694}},{"facility":"Chonnam National University Hospital, Department of Neurology","city":"Gwangju","zip":"501-757","country":"Korea, Republic of","geoPoint":{"lat":35.15472,"lon":126.91556}},{"facility":"Inha University Hospital, Department of Neurology","city":"Incheon","zip":"400-711","country":"Korea, Republic of","geoPoint":{"lat":37.45646,"lon":126.70515}},{"facility":"Seoul National University Hospital","city":"Seoul","zip":"110-744","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Severance Hospital, Yonsei University College of Medicine, Department of Neurology","city":"Seoul","zip":"120-752","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center, Department of Neurology","city":"Seoul","zip":"135710","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center, Department of Neurology","city":"Seoul","zip":"138-736","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Chang Gung Medical Foundation-Kaohsiung Chang Gung Memorial Hospital","city":"Kaohsiung","zip":"833","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"China Medical University Hospital","city":"Taichung","zip":"404","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"National Taiwan University Hospital","city":"Taipei","zip":"100","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"facility":"Chang Gung Medical Foundation-Linkou Branch","city":"Taoyuan County","zip":"333","country":"Taiwan"}]},"referencesModule":{"references":[{"pmid":"26738812","type":"DERIVED","citation":"Di Cesare F, Mancuso J, Woodward P, Bednar MM, Loudon PT; A9541004 Stroke Study Group. Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial. J Stroke Cerebrovasc Dis. 2016 Mar;25(3):642-9. doi: 10.1016/j.jstrokecerebrovasdis.2015.11.026. Epub 2015 Dec 28."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9541004&StudyName=Study%20Evaluating%20The%20Safety%20And%20Efficacy%20Of%20PF-03049423%20In%20Subjects%20With%20Ischemic%20Stroke"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 181 participants were assigned to study treatment, 178 of which received study treatment.","groups":[{"id":"FG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"FG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days."},{"id":"FG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"FG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-0304942 3 mg once daily for 90 days."},{"id":"FG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"FG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"70"},{"groupId":"FG005","numSubjects":"67"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"7"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"46"},{"groupId":"FG005","numSubjects":"46"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"24"},{"groupId":"FG005","numSubjects":"21"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"5"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"5"}]},{"type":"Did not meet entrance criteria","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Medication error without adverse event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}]},{"type":"Study terminated by sponsor","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"10"},{"groupId":"FG005","numSubjects":"7"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The Full Analysis Set (FAS) consisted of all randomized participants who took any study medication (active or placebo).","groups":[{"id":"BG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"BG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days."},{"id":"BG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"BG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-0304942 3 mg once daily for 90 days."},{"id":"BG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"BG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"70"},{"groupId":"BG005","value":"67"},{"groupId":"BG006","value":"178"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.3","spread":"14.3"},{"groupId":"BG001","value":"64.7","spread":"6.0"},{"groupId":"BG002","value":"69.8","spread":"8.3"},{"groupId":"BG003","value":"65.8","spread":"13.4"},{"groupId":"BG004","value":"64.2","spread":"13.1"},{"groupId":"BG005","value":"65.6","spread":"11.3"},{"groupId":"BG006","value":"65.1","spread":"12.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"28"},{"groupId":"BG005","value":"26"},{"groupId":"BG006","value":"70"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"42"},{"groupId":"BG005","value":"41"},{"groupId":"BG006","value":"108"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Any Abnormal Laboratory Test Results (Part 1* and 2)","description":"The total number of participants with laboratory test abnormalities (without regard to baseline abnormality) was assessed. \\*This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.","populationDescription":"The FAS consisted of all randomized participants who took any study medication (active or placebo). Participants analyzed indicated number of participants evaluated.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 (Baseline) up to Day 90","groups":[{"id":"OG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days."},{"id":"OG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-0304942 3 mg once daily for 90 days."},{"id":"OG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"70"},{"groupId":"OG005","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"64"},{"groupId":"OG005","value":"56"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Vital Signs Data Met Criteria of Potential Clinical Concern (Part 1* and 2)","description":"Vital signs included blood pressure (BP; supine, sitting and standing) and pulse rate. Vital signs criteria of potential clinical concern were 1), BP: systolic BP (SBP) greater than or equal to (\\>=) 30 or 50 millimeters of mercury (mm Hg) change from grand baseline in same posture, systolic less than (\\<) 90 mm Hg; diastolic BP (DBP) \\>=20 mm Hg change from grand baseline in same posture, diastolic \\<50 mm Hg; 2), pulse rate (supine, sitting and standing): \\<40 or greater than (\\>) 120 beats per minute (bpm); Standing: \\<40 or \\>140 bpm. \\*This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.","populationDescription":"The FAS consisted of all randomized participants who took any study medication (active or placebo). n=number of evaluable participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 (Baseline) up to follow-up (28 days after Day 90)","groups":[{"id":"OG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days."},{"id":"OG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-0304942 3 mg once daily for 90 days."},{"id":"OG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"70"},{"groupId":"OG005","value":"67"}]}],"classes":[{"title":"Supine SBP <90 mm Hg, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}]},{"title":"Sitting SBP <90 mm Hg, n=10,8,9,5,55,59","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}]},{"title":"Standing SBP <90 mm Hg, n=7,7,9,8,49,48","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"}]}]},{"title":"Supine DBP <50 mm Hg, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"4"}]}]},{"title":"Sitting DBP <50 mm Hg, n=10,8,9,5,55,59","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"}]}]},{"title":"Standing DBP <50 mm Hg, n=7,7,9,8,49,48","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"}]}]},{"title":"Supine pulse rate <40 bpm, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Supine pulse rate >120 bpm, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"7"}]}]},{"title":"Increase:supine SBP >=30 mm Hg, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"17"}]}]},{"title":"Increase: sitting SBP >=30 mm Hg, n=9,6,9,4,48,44","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"9"}]}]},{"title":"Increase: standing SBP >=30 mm Hg, n=2,3,3,6,19,22","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]}]},{"title":"Increase:supine DBP >=20 mm Hg, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"22"}]}]},{"title":"Increase: sitting DBP >=20 mm Hg, n=9,6,9,4,48,44","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"12"}]}]},{"title":"Increase: standing DBP >=20 mm Hg, n=2,3,3,6,19,22","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"}]}]},{"title":"Decrease:supine SBP >=30 mm Hg, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"37"}]}]},{"title":"Decrease: sitting SBP >=30 mm Hg, n=9,6,9,4,48,44","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"18"}]}]},{"title":"Decrease: standing SBP >=30 mm Hg, n=2,3,3,6,19,22","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"11"}]}]},{"title":"Decrease:supine DBP >=20 mm Hg, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"26"}]}]},{"title":"Decrease: sitting DBP >=20 mm Hg, n=9,6,9,4,48,44","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"14"}]}]},{"title":"Decrease: standing DBP >=20 mm Hg, n=2,3,3,6,19,22","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"11"}]}]},{"title":"Decrease:supine SBP >=50 mm Hg, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"9"}]}]},{"title":"Decrease: sitting SBP >=50 mm Hg, n=9,6,9,4,48,44","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"6"}]}]},{"title":"Decrease: standing SBP >=50 mm Hg, n=2,3,3,6,19,22","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"}]}]},{"title":"Sitting pulse rate <40 bpm, n=1,0,2,0,3,2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"NA","comment":"No participants were evaluated."},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"NA","comment":"No participants were evaluated"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Standing pulse rate <40 bpm, n=0,0,0,2,1,0","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"No participants were evaluated."},{"groupId":"OG001","value":"NA","comment":"No participants were evaluated."},{"groupId":"OG002","value":"NA","comment":"No participants were evaluated."},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"NA","comment":"No participants were evaluated."}]}]},{"title":"Sitting pulse rate >120 bpm, n=1,0,2,0,3,2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"NA","comment":"No participants were evaluated."},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"NA","comment":"No participants were evaluated."},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Standing pulse rate >140 bpm, n=0,0,0,2,1,0","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"No participants were evaluated."},{"groupId":"OG001","value":"NA","comment":"No participants were evaluated."},{"groupId":"OG002","value":"NA","comment":"No participants were evaluated."},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"NA","comment":"No participants were evaluated."}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Electrocardiograms (ECGs) Data Met Criteria of Potential Clinical Concern (Part 1* and 2)","description":"ECG criteria of potential clinical concern were 1), PR interval: \\>=300 milliseconds (msec); \\>=25% increase when baseline \\>200 msec; or increase \\>=50% when baseline \\<=200 msec; 2), QRS interval: \\>=140 msec; \\>=50% increase from baseline; 3), QT interval: \\>=500 msec, QTc interval using Fridericia's formula (QTcF interval): absolute value \\>=450 - \\<480 msec, \\>=480-\\<500 msec, \\>=500 msec; absolute change 30 - \\<60, \\>=60 msec. \\*This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.","populationDescription":"The FAS consisted of all randomized participants who took any study medication (active or placebo). n=number of evaluable participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 (Baseline) to Day 90","groups":[{"id":"OG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days."},{"id":"OG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-0304942 3 mg once daily for 90 days."},{"id":"OG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"70"},{"groupId":"OG005","value":"67"}]}],"classes":[{"title":"PR interval >=300 msec, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"QRS interval >=140 msec, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]},{"title":"QT interval >=500 msec, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"}]}]},{"title":"QTcF interval 450-480 msec, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"14"}]}]},{"title":"QTcF interval 480-500 msec, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}]}]},{"title":"QTcF interval >=500 msec, n=11,9,11,10,70,67","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]},{"title":"PR interval increase >=25%/50%, n=10,7,9,9,52,47","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"QRS interval increase >=50%, n=10,9,11,10,69,66","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]},{"title":"QTcF increase 30-60 msec, n=10,9,11,10,69,66","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"11"}]}]},{"title":"QTcF increase >=60 msec, n=10,9,11,10,69,66","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Significant Change in Physical Examination Findings (Part 1* and 2)","description":"The complete physical examination included examination of the skin, eyes, ears, throat, neck, cardiac, respiratory, gastrointestinal, and musculoskeletal systems. The limited physical examination included examination of the cardiac, respiratory, gastrointestinal, and musculoskeletal systems. \\*This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.","populationDescription":"The FAS consisted of all randomized participants who took any study medication (active or placebo). Participants analyzed indicated those who had physical examinations done at both baseline and last visit.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 (Baseline) up to Day 90","groups":[{"id":"OG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days."},{"id":"OG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-0304942 3 mg once daily for 90 days."},{"id":"OG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"70"},{"groupId":"OG005","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Significant Change in Neurological Examination Findings (Part 1* and 2)","description":"The complete neurological examination included an assessment of the motor, sensory, cranial nerves, reflexes, mental status and associated motor functions. The limited neurological exam could examine the same categories of neurologic assessments as the full examination, but would differ by the depth in the examination. The examination was required to be done to the extent needed to assess the participant for any potential changes in neurological status, as determined by the Investigator, but had to always include an assessment of motor, vision and hearing. \\*This endpoint was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for this timeframe were not reported separately, Part 1 and 2 data were reported together.","populationDescription":"The FAS consisted of all randomized participants who took any study medication (active or placebo). Participants analyzed indicated those who had neurological examinations done at both baseline and last visit.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 1 (Baseline) up to Day 90","groups":[{"id":"OG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days."},{"id":"OG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-0304942 3 mg once daily for 90 days."},{"id":"OG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"70"},{"groupId":"OG005","value":"66"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Suicidal Behavior and/or Ideation as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) (Part 1* and 2)","description":"Data were mapped to Columbia-Classification Algorithm of Suicide Assessment (C-CASA) event codes. C-SSRS assessed if participant experienced: completed suicide (Code 1), suicide attempt (Code 2) (Response of \"Yes\" on \"actual attempt\"), preparatory acts toward imminent suicidal behavior (Code 3) (\"Yes\" on \"aborted attempt\", \"interrupted attempt\", \"preparatory acts or behavior\"), suicidal ideation (Code 4) (\"Yes\" on \"wish to be dead\", \"non-specific active suicidal thoughts\", \"active suicidal ideation with methods without intent to act/some intent to act without specific plan or with specific plan and intent), self-injurious behavior, no suicidal intent (Code 7) (\"Yes\" on \"Has participant engaged in non-suicidal self-injurious behavior\"). Number of participants with \"Yes\" response for any of above mentioned categories was assessed. \\*This was a primary endpoint for Part 1 (timeframe Days 1 to 14), as data for it were not reported separately, Part 1 and 2 data were reported together.","populationDescription":"The FAS consisted of all randomized participants who took any study medication (active or placebo). n=number of participants who had C-SSRS assessed at that visit.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 7 (Baseline) up to follow up (28 days after Day 90)","groups":[{"id":"OG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days."},{"id":"OG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-0304942 3 mg once daily for 90 days."},{"id":"OG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"70"},{"groupId":"OG005","value":"67"}]}],"classes":[{"title":"Day 7, n=0, 0, 1, 1, 64, 57","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"No participants had C-SSRS assessed."},{"groupId":"OG001","value":"NA","comment":"No participants had C-SSRS assessed."},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"}]}]},{"title":"Day 14, n=0, 0, 1, 1, 59, 53","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"No participants had C-SSRS assessed."},{"groupId":"OG001","value":"NA","comment":"No participants had C-SSRS assessed."},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Day 30, n=0, 0, 1, 1, 60, 47","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"No participants had C-SSRS assessed."},{"groupId":"OG001","value":"NA","comment":"No participants had C-SSRS assessed."},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}]},{"title":"Day 60, n=0, 0, 1, 1, 55, 44","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"No participants had C-SSRS assessed."},{"groupId":"OG001","value":"NA","comment":"No participants had C-SSRS assessed."},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}]},{"title":"Day 90, n=0, 0, 1, 1, 61, 53","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"No participants had C-SSRS assessed."},{"groupId":"OG001","value":"NA","comment":"No participants had C-SSRS assessed."},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"}]}]},{"title":"Follow-up, n=0, 0, 1, 1, 59, 51","categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"No participants had C-SSRS assessed."},{"groupId":"OG001","value":"NA","comment":"No participants had C-SSRS assessed."},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Modified Rankin Scale (mRS) Less Than or Equal to (<=2) at Day 90 (Part 2)","description":"The mRS is a 6-point scale of functional recovery. The scale grades participants as having no symptoms (0), minor symptoms (1), minor handicap (2), moderate handicap (3), moderately severe handicap (4), severe handicap (5), or death (6).","populationDescription":"The Inferential Full Analysis Set (I-FAS) consisted of participants within the FAS who were randomized to PF-03049423 maximum tolerated dose (MTD) or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). n=number of participants included for comparison between active drug and placebo.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"Last Observation Carried Forward (LOCF), n=68, 65","categories":[{"measurements":[{"groupId":"OG000","value":"42.6"},{"groupId":"OG001","value":"46.2"}]}]},{"title":"Observed Cases (OC), n=51, 52","categories":[{"measurements":[{"groupId":"OG000","value":"47.1"},{"groupId":"OG001","value":"50.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4962","statisticalMethod":"Regression, Logistic","statisticalComment":"LOCF was used to impute missing data.","paramType":"Odds Ratio (OR)","paramValue":"0.735","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.41","ciUpperLimit":"1.31"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2517","statisticalMethod":"Regression, Logistic","statisticalComment":"The analysis was based on OC.","paramType":"Odds Ratio (OR)","paramValue":"0.561","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.29","ciUpperLimit":"1.07"}]},{"type":"SECONDARY","title":"Change From Baseline in Box and Blocks (B&B) Test at Day 90 for Paretic Hand (Part 2)","description":"The B\\&B test is a measure of manual dexterity. The B\\&B apparatus consists of a box divided into 2 sections and 1-inch hardwood blocks. The blocks began in the compartment of the test box to the dominant side of the participant. The participant was required to transfer the blocks one at a time to the other side of the box as quickly as possible in 1 minute using the non-paretic hand. The box was then turned so all the blocks were in the same side as the paretic hand. The participant was then required to do the test with his/her paretic hand. The participant was told that if more than 1 block was picked up at a time it was to only count as 1 block. The participant was also told that their fingertips needed to cross the partition for the block to be counted. The performance measure for this task was the number of blocks moved within 1 minute.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). Number of participants indicated those participants included for comparison between active drug and placebo.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"blocks moved per minute","timeFrame":"Day 1 (Baseline), Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"24"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.881","spread":"3.8667"},{"groupId":"OG001","value":"26.741","spread":"3.5627"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Paretic hand","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9716","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.141","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.972","ciUpperLimit":"5.254","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"3.9420"}]},{"type":"SECONDARY","title":"Change From Baseline in Box and Blocks (B&B) Test at Day 90 for Paretic to Non-paretic Hand Ratio (Part 2)","description":"The B\\&B test is a measure of manual dexterity. The B\\&B apparatus consists of a box divided into 2 sections and 1-inch hardwood blocks. The blocks began in the compartment of the test box to the dominant side of the participant. The participant was required to transfer the blocks one at a time to the other side of the box as quickly as possible in 1 minute using the non-paretic hand. The box was then turned so all the blocks were in the same side as the paretic hand. The participant was then required to do the test with his/her paretic hand. The participant was told that if more than 1 block was picked up at a time it was to only count as 1 block. The participant was also told that their fingertips needed to cross the partition for the block to be counted. The performance measure for this task was the number of blocks moved within 1 minute.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). Number of participants indicated those participants included for comparison between active drug and placebo.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage change","timeFrame":"Day 1 (Baseline), Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"24"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.830","spread":"7.7810"},{"groupId":"OG001","value":"31.041","spread":"7.1284"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Paretic to non-paretic hand ratio (%)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1417","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"10.789","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.401","ciUpperLimit":"20.177","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"7.2392"}]},{"type":"SECONDARY","title":"Change From Baseline in Hand Grip Strength Test at Day 90 for Paretic and Non-paretic Hands (Part 2)","description":"The Hand Grip Strength Test measures the maximum isometric strength of the hand and forearm muscles. The participant was required to squeeze the dynamometer with maximum isometric effort while sitting with shoulder adducted and neutrally roated, elbow flexed at 90 degrees and the forearm in neutral position and wrist between 0 to 30 degrees dorsiflexion and a 0 to 15 degrees ulnar deviation. The participant performed this task 3 times with each hand, starting with the non-paretic hand. The performance measure for this task was the average score measured in pounds of pressure exerted.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). n=number of participants included for comparison between active drug and placebo.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pounds","timeFrame":"Day 1 (Baseline), Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"Paretic Hand, n=26, 26","categories":[{"measurements":[{"groupId":"OG000","value":"20.556","spread":"4.1829"},{"groupId":"OG001","value":"30.886","spread":"3.9964"}]}]},{"title":"Non-Paretic Hand, n=46, 41","categories":[{"measurements":[{"groupId":"OG000","value":"12.546","spread":"2.3612"},{"groupId":"OG001","value":"12.312","spread":"2.5029"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Paretic hand","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0611","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-10.330","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-17.351","ciUpperLimit":"-3.310","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"5.4241"},{"groupIds":["OG000","OG001"],"groupDescription":"Non-paretic hand","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9433","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.235","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.011","ciUpperLimit":"4.480","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"3.2899"}]},{"type":"SECONDARY","title":"Change From Baseline in Hand Grip Strength Test at Day 90 for Paretic to Non-paretic Hand Ratio (Part 2)","description":"The Hand Grip Strength Test measures the maximum isometric strength of the hand and forearm muscles. The participant was required to squeeze the dynamometer with maximum isometric effort while sitting with shoulder adducted and neutrally roated, elbow flexed at 90 degrees and the forearm in neutral position and wrist between 0 to 30 degrees dorsiflexion and a 0 to 15 degrees ulnar deviation. The participant performed this task 3 times with each hand, starting with the non-paretic hand. The performance measure for this task was the average score measured in pounds of pressure exerted.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). Number of participants analyzed indicated those participants included for comparison between active drug and placebo.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage change","timeFrame":"Day 1 (Baseline), Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.949","spread":"5.4499"},{"groupId":"OG001","value":"36.761","spread":"5.1182"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Paretic to non-paretic hand ratio (%)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0654","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-12.812","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-21.668","ciUpperLimit":"-3.957","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"6.8448"}]},{"type":"SECONDARY","title":"Percentage of Participants With mRS (0-1) at Day 90 (Part 2)","description":"The mRS is a 6-point scale of functional recovery. The scale grades participants as having no symptoms (0), minor symptoms (1), minor handicap (2), moderate handicap (3), moderately severe handicap (4), severe handicap (5), or death (6).","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"},{"groupId":"OG001","value":"24.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"LOCF was used to impute missing data.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9510","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.972","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.54","ciUpperLimit":"1.76"}]},{"type":"SECONDARY","title":"Percentage of Participants With National Institutes of Health Stroke Scale (NIHSS) (0-1) at Day 90 (Part 2)","description":"The NIHSS is a graded 11-item neurological examination rating speech and language, cognition, visual field deficits, motor and sensory impairments and ataxia used for the clinical assessment of acute stroke therapy. The maximum total score is 42 in a participant with a severe neurological deficit; the minimum score is 0 in a participant without gross neurological deficits.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"},{"groupId":"OG001","value":"26.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"LOCF was used to impute missing data.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7234","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"0.854","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.48","ciUpperLimit":"1.51"}]},{"type":"SECONDARY","title":"Change From Baseline in NIHSS at Day 90 (Part 2)","description":"The NIHSS is a graded 11-item neurological examination rating speech and language, cognition, visual field deficits, motor and sensory impairments and ataxia used for the clinical assessment of acute stroke therapy. The maximum total score is 42 in a participant with a severe neurological deficit; the minimum score is 0 in a participant without gross neurological deficits.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). Participants analyzed indicated number of participants included for comparison between active drug and placebo for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"unit on a scale","timeFrame":"Day 1 (Baseline), Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.511","spread":"0.5384"},{"groupId":"OG001","value":"-6.228","spread":"0.5655"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6759","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.283","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.156","ciUpperLimit":"0.589","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.6755"}]},{"type":"SECONDARY","title":"Percentage of Participants With Barthel Index (BI) >= 95 and BI =100 at Day 90 (Part 2)","description":"The BI is an index of independence to score the ability of a participant with a neuromuscular or musculoskeletal disorder to care for him or herself. The index rates a participant's ability on the following 10 activities: feeding, moving from wheelchair to bed, personal toilet, getting on and off toilet, bathing self, walking on level surface, ascending and descending stairs, dressing, controlling bowels and controlling bladder. The maximum total score is 100 in a participant without functional impairment; the minimum score is 0 in a participant with major functional impairment.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"BI >=95","categories":[{"measurements":[{"groupId":"OG000","value":"47.1"},{"groupId":"OG001","value":"40.0"}]}]},{"title":"BI=100","categories":[{"measurements":[{"groupId":"OG000","value":"42.6"},{"groupId":"OG001","value":"35.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"BI \\>=95, LOCF was used to impute missing data.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4213","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.433","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.81","ciUpperLimit":"2.54"},{"groupIds":["OG000","OG001"],"groupDescription":"BI=100, LOCF was used to impute missing data.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2760","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.651","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.92","ciUpperLimit":"2.98"}]},{"type":"SECONDARY","title":"BI at Day 90 (Part 2)","description":"The BI is an index of independence to score the ability of a participant with a neuromuscular or musculoskeletal disorder to care for him or herself. The index rates a participant's ability on the following 10 activities: feeding, moving from wheelchair to bed, personal toilet, getting on and off toilet, bathing self, walking on level surface, ascending and descending stairs, dressing, controlling bowels and controlling bladder. The maximum total score is 100 in a participant without functional impairment; the minimum score is 0 in a participant with major functional impairment.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). Participants analyzed indicated number of participants included for comparison between active drug and placebo for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"unit on a scale","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.151","spread":"3.6248"},{"groupId":"OG001","value":"73.552","spread":"3.8471"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2118","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"5.599","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.150","ciUpperLimit":"11.348","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"4.4547"}]},{"type":"SECONDARY","title":"Domains of Interest: Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Coding Sub Test at Day 90 (Part 2)","description":"The test uses a reference key, the participant had 90 seconds to pair specific numbers with given geometric figures. Responses could be written or oral. The performance measure for this task was the total number of correct responses.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). Participants analyzed indicated number of participants included for comparison between active drug and placebo for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"correct responses","timeFrame":"Day 1 (Baseline), Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.748","spread":"1.5321"},{"groupId":"OG001","value":"12.686","spread":"1.6282"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5541","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.062","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.252","ciUpperLimit":"3.375","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.7844"}]},{"type":"SECONDARY","title":"Domains of Interest: Change From Baseline in RBANS Naming Sub Test at Day 90 (Part 2)","description":"This test requires the participant to name 10 objects drawn in ink. The tester asked the participant to identify the picture. The participant had 20 seconds to respond to each picture presented. The performance measure was the number of objects named correctly.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). Participants analyzed indicated number of participants included for comparison between active drug and placebo for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"objects named correctly","timeFrame":"Day 1 (Baseline), Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.989","spread":"0.3676"},{"groupId":"OG001","value":"1.324","spread":"0.3666"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4260","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.334","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.874","ciUpperLimit":"0.205","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.4178"}]},{"type":"SECONDARY","title":"Domains of Interest: Change From Baseline in Line Cancellation Test [(L+R)/28 × 100%, (L/14) × 100%, (R/14) × 100%)] at Day 90 (Part 2)","description":"The participant was presented with a page that had lines placed across the page. The participant was required to cross out all the lines on the page using their non-paretic hand after the tester had demonstrated what was required by crossing out the center line. The performance measure for this task was the total number of omissions made expressed as a percentage of the total number of items in the test. The test contains 4 variables: (L+R)/28 × 100%, (L/14) × 100%, (R/14) × 100%, and (L-R)/(L+R), where L = number of lines crossed on the left side of the paper; R = number of lines crossed on the right side of the paper.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). n=number of participants included for comparison between active drug and placebo for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"change in percentage of lines crossed","timeFrame":"Day 1 (Baseline), Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"(L+R)/28 × 100%, n=39, 35","categories":[{"measurements":[{"groupId":"OG000","value":"19.459","spread":"4.4433"},{"groupId":"OG001","value":"16.983","spread":"4.4551"}]}]},{"title":"(L/14) × 100%, n=39, 35","categories":[{"measurements":[{"groupId":"OG000","value":"22.824","spread":"5.6691"},{"groupId":"OG001","value":"18.950","spread":"5.6639"}]}]},{"title":"(R/14) × 100%, n=39, 35","categories":[{"measurements":[{"groupId":"OG000","value":"16.481","spread":"4.3564"},{"groupId":"OG001","value":"15.431","spread":"4.3647"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"(L+R)/28 × 100%","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6500","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"2.477","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.547","ciUpperLimit":"9.500","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"5.4394"},{"groupIds":["OG000","OG001"],"groupDescription":"(L/14) × 100%","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.5671","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"3.874","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.834","ciUpperLimit":"12.583","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"6.7431"},{"groupIds":["OG000","OG001"],"groupDescription":"(R/14) × 100%","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8430","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"1.049","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.771","ciUpperLimit":"7.870","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"5.2816"}]},{"type":"SECONDARY","title":"Domains of Interest: Change From Baseline in Line Cancellation Test at Day 90 [(L-R)/(L+R)] (Part 2)","description":"The participant was presented with a page that had lines placed across the page. The participant was required to cross out all the lines on the page using their non-paretic hand after the tester had demonstrated what was required by crossing out the center line. The performance measure for this task was the total number of omissions made expressed as a percentage of the total number of items in the test. The test contains 4 variables: (L+R)/28 × 100%, (L/14) × 100%, (R/14) × 100%, and (L-R)/(L+R), where L = number of lines crossed on the left side of the paper; R = number of lines crossed on the right side of the paper.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). Number of participants analyzed indicated participants included for comparison between active drug and placebo for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"change in ratio","timeFrame":"Day 1 (Baseline), Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"34"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.083","spread":"0.0620"},{"groupId":"OG001","value":"-0.023","spread":"0.0625"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"(L R)/(L+R)","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1512","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.106","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.011","ciUpperLimit":"0.201","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.0733"}]},{"type":"SECONDARY","title":"Domains of Interest: Change From Baseline in Recognition Memory Test at Day 90 (Part 2)","description":"This test assesses the ability to recognize pictures of objects. The participant was presented a series of pictures, a subset of which were the objects presented in the RBANS Naming Sub Test. After each picture was presented, the participant indicated either manually (ie, affirmative head nod) or verbally whether the picture was seen previously. The participant was given 5 seconds per picture to respond. The performance measure for this task was the total number of pictures correctly identified.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). Participants analyzed indicated number of participants included for comparison between active drug and placebo for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"pictures correctly identified","timeFrame":"Day 1 (Baseline), Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.135","spread":"0.4743"},{"groupId":"OG001","value":"0.144","spread":"0.4797"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0128","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-1.279","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.929","ciUpperLimit":"-0.629","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.5041"}]},{"type":"SECONDARY","title":"Gait Velocity Test at Day 90 (Part 2)","description":"The 10-meter walk test requires a 20 meter straight path, with 5 meters for acceleration, 10 meters for steady state walking, and 5 meters for deceleration. Markers were placed at the 5 and 15 meter positions along the path. The participant began to walk \"at a comfortable pace\" at 1 end of the path, and continued walking until he/she reached the other end. The rater used a stopwatch to determine how much time it took for the participant to traverse the 10 meter center of the path, starting the stopwatch as soon as the participant's limb crossed the first marker and stopping the stopwatch as soon as the participant's limb crossed the second marker.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). Participants analyzed indicated number of participants included for comparison between active drug and placebo for this outcome measure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"meters/second (m/s)","timeFrame":"Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"36"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.064","spread":"0.1040"},{"groupId":"OG001","value":"0.975","spread":"0.1128"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.4713","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"0.089","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.070","ciUpperLimit":"0.248","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.1226"}]},{"type":"SECONDARY","title":"Plasma Concentrations of PF-03049423 (Part 1 and 2)","populationDescription":"PK concentration population included all participants who were treated with PF-03049423 who had at least 1 measurable concentration. n=participants with concentration above lower limit of quantification at the corresponding sampling time.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanogram/milliliter (ng/mL)","timeFrame":"Days 1, 2, 7, 14, 30, 60 and 90","groups":[{"id":"OG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"OG002","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"70"}]}],"classes":[{"title":"Day 1 (0 hour predose), n=0, 1, 3","categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"No participants had concentration above lower limit quantification."},{"groupId":"OG001","value":"0.05245","spread":"0.17397"},{"groupId":"OG002","value":"1.420","spread":"11.591"}]}]},{"title":"Day 1 (1 hour post dose), n=11, 10, 63","categories":[{"measurements":[{"groupId":"OG000","value":"5.825","spread":"4.3514"},{"groupId":"OG001","value":"17.50","spread":"12.814"},{"groupId":"OG002","value":"46.76","spread":"36.153"}]}]},{"title":"Day 1 (2 hours post dose), n=11, 11, 61","categories":[{"measurements":[{"groupId":"OG000","value":"7.063","spread":"3.2729"},{"groupId":"OG001","value":"30.18","spread":"11.313"},{"groupId":"OG002","value":"58.19","spread":"32.837"}]}]},{"title":"Day 1 (8 hours post dose), n=11, 11, 68","categories":[{"measurements":[{"groupId":"OG000","value":"7.361","spread":"2.4032"},{"groupId":"OG001","value":"25.39","spread":"8.6644"},{"groupId":"OG002","value":"52.47","spread":"23.250"}]}]},{"title":"Day 2 (0 hour, predose), n=11, 11, 67","categories":[{"measurements":[{"groupId":"OG000","value":"4.521","spread":"1.5265"},{"groupId":"OG001","value":"18.05","spread":"4.7834"},{"groupId":"OG002","value":"32.07","spread":"13.776"}]}]},{"title":"Day 7 (0 hour, post dose), n=9, 7, 64","categories":[{"measurements":[{"groupId":"OG000","value":"8.601","spread":"2.9609"},{"groupId":"OG001","value":"27.79","spread":"7.6945"},{"groupId":"OG002","value":"53.08","spread":"30.237"}]}]},{"title":"Day 7 (1 hour post dose), n=0, 1, 59","categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"No samples were collected."},{"groupId":"OG001","value":"51.80","spread":"NA","comment":"1 participant had concentration above lower limit of quantification, SD cannot be calculated."},{"groupId":"OG002","value":"115.9","spread":"65.329"}]}]},{"title":"Day 7 (2 hours post dose), n=0, 1, 59","categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"No samples were collected."},{"groupId":"OG001","value":"58.10","spread":"NA","comment":"1 participant had concentration above lower limit of quantification, SD cannot be calculated."},{"groupId":"OG002","value":"126.3","spread":"57.759"}]}]},{"title":"Day 7 (6 hours post dose), n=0, 1, 61","categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"No samples were collected."},{"groupId":"OG001","value":"51.10","spread":"NA","comment":"1 participant had concentration above lower limit of quantification, SD cannot be calculated."},{"groupId":"OG002","value":"103.8","spread":"41.090"}]}]},{"title":"Day 14 (0 hour predose), n=10, 8, 59","categories":[{"measurements":[{"groupId":"OG000","value":"7.805","spread":"2.9278"},{"groupId":"OG001","value":"31.13","spread":"9.8243"},{"groupId":"OG002","value":"53.10","spread":"28.085"}]}]},{"title":"Day 14 (1 hour post dose), n=9, 7, 0","categories":[{"measurements":[{"groupId":"OG000","value":"16.47","spread":"7.1782"},{"groupId":"OG001","value":"76.71","spread":"32.657"},{"groupId":"OG002","value":"NA","spread":"NA","comment":"No samples were collected."}]}]},{"title":"Day 14 (2 hours post dose), n=9, 6, 0","categories":[{"measurements":[{"groupId":"OG000","value":"17.06","spread":"7.3799"},{"groupId":"OG001","value":"70.37","spread":"14.795"},{"groupId":"OG002","value":"NA","spread":"NA","comment":"No samples were collected."}]}]},{"title":"Day 14 (6 [cohort 3:4] hours post dose), n=9,7,31","categories":[{"measurements":[{"groupId":"OG000","value":"17.57","spread":"4.1614"},{"groupId":"OG001","value":"58.36","spread":"11.720"},{"groupId":"OG002","value":"118.2","spread":"41.967"}]}]},{"title":"Day 30 (0 hour predose), n=6, 6, 58","categories":[{"measurements":[{"groupId":"OG000","value":"5.339","spread":"3.5712"},{"groupId":"OG001","value":"29.68","spread":"11.015"},{"groupId":"OG002","value":"50.77","spread":"31.473"}]}]},{"title":"Day 30 (4 hours post dose), n=2, 5, 25","categories":[{"measurements":[{"groupId":"OG000","value":"11.55","spread":"2.6234"},{"groupId":"OG001","value":"57.08","spread":"13.990"},{"groupId":"OG002","value":"96.27","spread":"49.929"}]}]},{"title":"Day 60 (0 hour predose), n=6, 6, 53","categories":[{"measurements":[{"groupId":"OG000","value":"6.360","spread":"3.1028"},{"groupId":"OG001","value":"24.55","spread":"5.8206"},{"groupId":"OG002","value":"49.37","spread":"33.747"}]}]},{"title":"Day 60 (4 hours post dose), n=2, 5, 27","categories":[{"measurements":[{"groupId":"OG000","value":"13.25","spread":"0.7778"},{"groupId":"OG001","value":"47.86","spread":"7.3296"},{"groupId":"OG002","value":"112.1","spread":"58.560"}]}]},{"title":"Day 90 (0 hour predose), n=5, 6, 45","categories":[{"measurements":[{"groupId":"OG000","value":"5.252","spread":"1.5161"},{"groupId":"OG001","value":"29.18","spread":"15.909"},{"groupId":"OG002","value":"47.02","spread":"24.065"}]}]},{"title":"Day 90 (4 hours post dose), n=2, 5, 20","categories":[{"measurements":[{"groupId":"OG000","value":"12.80","spread":"0.000"},{"groupId":"OG001","value":"49.40","spread":"13.962"},{"groupId":"OG002","value":"82.69","spread":"29.005"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"All-cause Mortality (Part 2)","description":"Deaths regardless causality were reported.","populationDescription":"The FAS consisted of all randomized participants who took any study medication (active or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of participants","timeFrame":"The time began from the participant provided informed consent through 28 calendar days post last administration of investigational product.","groups":[{"id":"OG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days."},{"id":"OG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-03049423 3 mg once daily for 90 days."},{"id":"OG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-03049423 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"70"},{"groupId":"OG005","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"7"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mortality Directly Related to Stroke (Part 2)","description":"Deaths caused by stroke were reported.","populationDescription":"The FAS consisted of all randomized participants who took any study medication (active or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of participants","timeFrame":"The time began from the participant provided informed consent through 28 calendar days post last administration of investigational product.","groups":[{"id":"OG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days."},{"id":"OG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-03049423 3 mg once daily for 90 days."},{"id":"OG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-03049423 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"70"},{"groupId":"OG005","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Neuro-worsening (Part 2)","description":"NIHSS change of 4 points or greater.","populationDescription":"The FAS consisted of all randomized participants who took any study medication (active or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of participants","timeFrame":"Day 1 (Baseline) up to Day 90","groups":[{"id":"OG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days."},{"id":"OG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-03049423 3 mg once daily for 90 days."},{"id":"OG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-03049423 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"70"},{"groupId":"OG005","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"No data were reported separately for this outcome measure, which was instead included in routine clinical review of NIHSS data."},{"groupId":"OG001","value":"NA","comment":"No data were reported separately for this outcome measure, which was instead included in routine clinical review of NIHSS data."},{"groupId":"OG002","value":"NA","comment":"No data were reported separately for this outcome measure, which was instead included in routine clinical review of NIHSS data."},{"groupId":"OG003","value":"NA","comment":"No data were reported separately for this outcome measure, which was instead included in routine clinical review of NIHSS data."},{"groupId":"OG004","value":"NA","comment":"No data were reported separately for this outcome measure, which was instead included in routine clinical review of NIHSS data."},{"groupId":"OG005","value":"NA","comment":"No data were reported separately for this outcome measure, which was instead included in routine clinical review of NIHSS data."}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With SBP <100 mm Hg or SBP Decline >=30 mm Hg From Immediate Pre-dose Measurement, With or Without Neuro-worsening (Defined as an NIHSS Increase of 4 Points or Greater) Within 2 Hours Post-dose (Part 2)","populationDescription":"The FAS consisted of all randomized participants who took any study medication (active or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of participants","timeFrame":"Day 1 (Baseline) up to Day 14","groups":[{"id":"OG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days."},{"id":"OG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-03049423 3 mg once daily for 90 days."},{"id":"OG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-03049423 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"70"},{"groupId":"OG005","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","comment":"No data were reported separately for this outcome measure, which was instead included in routine clinical review of BP data."},{"groupId":"OG001","value":"NA","comment":"No data were reported separately for this outcome measure, which was instead included in routine clinical review of BP data."},{"groupId":"OG002","value":"NA","comment":"No data were reported separately for this outcome measure, which was instead included in routine clinical review of BP data."},{"groupId":"OG003","value":"NA","comment":"No data were reported separately for this outcome measure, which was instead included in routine clinical review of BP data."},{"groupId":"OG004","value":"NA","comment":"No data were reported separately for this outcome measure, which was instead included in routine clinical review of BP data."},{"groupId":"OG005","value":"NA","comment":"No data were reported separately for this outcome measure, which was instead included in routine clinical review of BP data."}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Treatment-emergent Adverse Events (AEs) Resulting in Discontinuation of Study Drug (Part 2)","description":"An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.","populationDescription":"The FAS consisted of all randomized participants who took any study medication (active or placebo).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Number of participants","timeFrame":"Day 1 (Baseline) up to follow-up (28 days after Day 90)","groups":[{"id":"OG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days."},{"id":"OG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days."},{"id":"OG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-03049423 3 mg once daily for 90 days."},{"id":"OG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-03049423 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"70"},{"groupId":"OG005","value":"67"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Box and Blocks (B&B) Test at Day 90 for Non-paretic Hand (Part 2)","description":"The B\\&B test is a measure of manual dexterity. The B\\&B apparatus consists of a box divided into 2 sections and 1-inch hardwood blocks. The blocks began in the compartment of the test box to the dominant side of the participant. The participant was required to transfer the blocks one at a time to the other side of the box as quickly as possible in 1 minute using the non-paretic hand. The box was then turned so all the blocks were in the same side as the paretic hand. The participant was then required to do the test with his/her paretic hand. The participant was told that if more than 1 block was picked up at a time it was to only count as 1 block. The participant was also told that their fingertips needed to cross the partition for the block to be counted. The performance measure for this task was the number of blocks moved within 1 minute.","populationDescription":"The I-FAS consisted of participants within the FAS who were randomized to PF-03049423 MTD or highest dose (6 mg) group or the placebo group that was in the same cohort as the MTD or highest dose (6 mg). Number of participants indicated those participants included for comparison between active drug and placebo.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"blocks moved per minute","timeFrame":"Day 1 (Baseline), Day 90","groups":[{"id":"OG000","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days."},{"id":"OG001","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"41"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.797","spread":"2.1676"},{"groupId":"OG001","value":"18.313","spread":"2.2407"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Non-paretic hand","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8501","statisticalMethod":"Mixed Models Analysis","paramType":"Mean Difference (Final Values)","paramValue":"-0.516","ciPctValue":"80","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.026","ciUpperLimit":"2.995","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"2.7201"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From the time the subject had taken at least 1 dose of study treatment through last subject visit. For SAEs, the time began from the subject provided informed consent through 28 calendar days post last administration of investigational product.","description":"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","eventGroups":[{"id":"EG000","title":"Cohort 1: PF-03049423 1 mg","description":"Participants received PF-03049423 1 mg once daily for 90 days.","seriousNumAffected":2,"seriousNumAtRisk":11,"otherNumAffected":10,"otherNumAtRisk":11},{"id":"EG001","title":"Cohort 1: Placebo","description":"Participants received placebo matched to PF-03049423 1 mg once daily for 90 days.","seriousNumAffected":1,"seriousNumAtRisk":9,"otherNumAffected":7,"otherNumAtRisk":9},{"id":"EG002","title":"Cohort 2: PF-03049423 3 mg","description":"Participants received PF-03049423 3 mg once daily for 90 days.","seriousNumAffected":3,"seriousNumAtRisk":11,"otherNumAffected":7,"otherNumAtRisk":11},{"id":"EG003","title":"Cohort 2: Placebo","description":"Participants received placebo matched to PF-0304942 3 mg once daily for 90 days.","seriousNumAffected":1,"seriousNumAtRisk":10,"otherNumAffected":9,"otherNumAtRisk":10},{"id":"EG004","title":"Cohort 3: PF-03049423 6 mg","description":"Participants received PF-03049423 6 mg once daily for 90 days.","seriousNumAffected":15,"seriousNumAtRisk":70,"otherNumAffected":50,"otherNumAtRisk":70},{"id":"EG005","title":"Cohort 3: Placebo","description":"Participants received placebo matched to PF-0304942 6 mg once daily for 90 days.","seriousNumAffected":18,"seriousNumAtRisk":67,"otherNumAffected":47,"otherNumAtRisk":67}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Ileus paralytic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Condition aggravated","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Electrocardiogram ST-T change","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Metastases to bone","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Ischaemic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Subarachnoid haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Disorientation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Asphyxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":3,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":4,"numAtRisk":70},{"groupId":"EG005","numAffected":3,"numAtRisk":67}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Neutrophilia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":2,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":2,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Coronary artery occlusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Supraventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Atrial septal defect","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":2,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":2,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Conjunctival hyperaemia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Eye disorder","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":2,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":8,"numAtRisk":70},{"groupId":"EG005","numAffected":14,"numAtRisk":67}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":9,"numAtRisk":70},{"groupId":"EG005","numAffected":10,"numAtRisk":67}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":3,"numAtRisk":67}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":2,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":2,"numAtRisk":70},{"groupId":"EG005","numAffected":4,"numAtRisk":67}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":2,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":4,"numAtRisk":67}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Feeling cold","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":2,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":3,"numAtRisk":70},{"groupId":"EG005","numAffected":3,"numAtRisk":67}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":2,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":7,"numAtRisk":70},{"groupId":"EG005","numAffected":6,"numAtRisk":67}]},{"term":"Genitourinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":3,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":8,"numAtRisk":70},{"groupId":"EG005","numAffected":8,"numAtRisk":67}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Excoriation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":3,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":2,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":2,"numAtRisk":70},{"groupId":"EG005","numAffected":4,"numAtRisk":67}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":2,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Lip injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Radius fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Alanine aminotransferase abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":3,"numAtRisk":67}]},{"term":"Aspartate aminotransferase abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":4,"numAtRisk":67}]},{"term":"Blood bilirubin abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Blood potassium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":2,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Red blood cells urine positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"White blood cells urine positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Fluid imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":7,"numAtRisk":70},{"groupId":"EG005","numAffected":3,"numAtRisk":67}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":3,"numAtRisk":70},{"groupId":"EG005","numAffected":3,"numAtRisk":67}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":2,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Gouty arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":2,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":3,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":9,"numAtRisk":70},{"groupId":"EG005","numAffected":4,"numAtRisk":67}]},{"term":"Dementia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":3,"numAtRisk":67}]},{"term":"Haemorrhagic transformation stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":11},{"groupId":"EG001","numAffected":3,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":5,"numAtRisk":70},{"groupId":"EG005","numAffected":7,"numAtRisk":67}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":2,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":5,"numAtRisk":70},{"groupId":"EG005","numAffected":3,"numAtRisk":67}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":4,"numAtRisk":70},{"groupId":"EG005","numAffected":4,"numAtRisk":67}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":2,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":7,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":4,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Albuminuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":5,"numAtRisk":70},{"groupId":"EG005","numAffected":4,"numAtRisk":67}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":7,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Renal cyst","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Urethral haemorrhage","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":3,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":2,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Bronchiectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":4,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":3,"numAtRisk":67}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Pulmonary congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Dermatitis diaper","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":5,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":0,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":1,"numAtRisk":67}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":11},{"groupId":"EG003","numAffected":0,"numAtRisk":10},{"groupId":"EG004","numAffected":1,"numAtRisk":70},{"groupId":"EG005","numAffected":0,"numAtRisk":67}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":4,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":3,"numAtRisk":70},{"groupId":"EG005","numAffected":2,"numAtRisk":67}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":11},{"groupId":"EG003","numAffected":1,"numAtRisk":10},{"groupId":"EG004","numAffected":4,"numAtRisk":70},{"groupId":"EG005","numAffected":7,"numAtRisk":67}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"The study was terminated prematurely due to demonstrated futility at interim analysis. The final results are consistent with interim results."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Mexico"]},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"C000549061","term":"3-(4-(2-hydroxyethyl)piperazin-1-yl)-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido(3,4-b)pyrazin-2(1H)-one"}],"ancestors":[{"id":"D000058986","term":"Phosphodiesterase 5 Inhibitors"},{"id":"D000010726","term":"Phosphodiesterase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M11136","name":"Mebendazole","relevance":"LOW"},{"id":"M1815","name":"Piperazine","relevance":"LOW"},{"id":"M234834","name":"Piperazine citrate","relevance":"LOW"},{"id":"M256289","name":"DMP 777","relevance":"LOW"},{"id":"M251916","name":"3-(4-(2-hydroxyethyl)piperazin-1-yl)-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido(3,4-b)pyrazin-2(1H)-one","asFound":"Apixaban 2.5 mg","relevance":"HIGH"},{"id":"M29022","name":"Phosphodiesterase 5 Inhibitors","relevance":"LOW"},{"id":"M13319","name":"Phosphodiesterase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}